The results of operations for the periods reflected herein are not necessarily indicative of results that may be expected for future periods.

We continue to recover from the economic effects of the COVID-19 pandemic. During the three and six months ended June 30, 2022, we had decreases of $1.0 million and $0.8 million, respectively, in Healthcare division revenue and increases of $5.9 million and $8.5 million, respectively, in Construction division revenue as compared to the same period of the prior year.

Critical Accounting Policies and Estimates

Form 10-K for the fiscal year ended December 31, 2021 have the greatest potential impact on our financial statements, so we consider them to be our critical accounting policies and estimates.

Comparison of the Three Months Ended June 30, 2022 and 2021

The following table summarizes our results for the three months ended June 30, 2022 and 2021 (in thousands):

*Percentage may not add due to rounding

Healthcare revenue is summarized as follows (in thousands):

Healthcare revenue decreased 6.4% compared to the prior year quarter, driven by a decrease in revenue from fewer total scanning days due to the national shortage of Nuclear Medicine Technologists.

Construction revenue is summarized as follows (in thousands):

The increase in Healthcare gross margin percentage was mainly driven by an improved mix of product and service revenues for the three months ended June 30, 2022, compared to the same period in the prior year.

Investments gross loss is summarized as follows (in thousands):

The gross loss relates to depreciation expense associated with the three manufacturing facilities acquired in April 2019.

Operating expenses are summarized as follows (in thousands):

Total other income (expense) is summarized as follows (in thousands):

Other (expenses) income, net, for the three months ended June 30, 2022 and 2021 are predominately comprised of unrealized gain from available for sale securities, and finance costs.

Interest expense, net, for the three months ended June 30, 2022 and 2021 are predominantly comprised of interest costs and the related amortization of deferred issuance costs on our debt, respectively.

For the three months ended June 30, 2022 and 2021 we recorded an income tax benefit of $327 thousand and expense of $32 thousand, respectively, within continuing operations. See Note 10. Income Taxes, within the notes to our condensed consolidated financial statements for further information related to the income taxes.

See Note 2. Discontinued Operations of the condensed consolidated financial statements for information regarding discontinued operations.

Comparison of the Six Months Ended June 30, 2022 and 2021

The following table summarizes our results for the six months ended June 30, 2022 and 2021 (in thousands):

*Percentage to revenue were computed independently for each discrete item presented. Therefore, the sum of the individual items may not equal the total.

Healthcare revenue by segments is summarized as follows (in thousands):

Construction revenue is summarized as follows (in thousands):

The increase in Healthcare gross margin percentage was mainly driven by an improved mix of product and service revenues.

Investments gross loss and margin is summarized as follows (in thousands):

The Investments gross loss relates to depreciation expense associated with the three manufacturing facilities acquired in April 2019.

Operating expenses are summarized as follows (in thousands):

On February 1, 2021, we completed the sale of our MD Office Solutions business and recognized $0.8 million in gain upon sale.

Total other expense is summarized as follows (in thousands):

Interest expense, net, for the six months ended June 30, 2022 and 2021 is predominantly comprised of interest costs and the related amortization of deferred issuance costs on our debt.

See Note 2, Discontinued Operations of the condensed consolidated financial statements for information regarding discontinued operations.

Cash Flows from Operating Activities

Cash Flows from Investing Activities

Cash Flows from Financing Activities

The following table shows cash flow information for the six months ended June 30, 2022 and 2021 (in thousands):

See Note 14. Equity Transactions in the accompanying notes to the condensed consolidated financial statements for further details.

From April 2020 through May 2020, the Company and its subsidiaries received $6.7 million of loans under the Paycheck Protection Program ("PPP"). Total PPP loans received the Construction division and Healthcare division were $5.5 million and $1.2 million, respectively.

All PPP loans were forgiven, resulting in a gain of $4.2 million in 2021 and $2.5 million in 2020.

See Note 8. Debt in the accompanying notes to the financial statements for further details.

© Edgar Online, source Glimpses